900174-43-8

Basic information

• Product Name: 1-BroMo-2-(isopropanesulfonyl)benzene
• Synonyms: 1-BroMo-2-(isopropanesulfonyl)benzene;1-bromo-2-(isopropylsulfonyl)benzene
• CAS NO: 900174-43-8
• Molecular Formula: C₉H₁₁BrO₂S
• Molecular Weight: 263.15144
• Mol File: 900174-43-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BroMo-2-(isopropanesulfonyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BroMo-2-(isopropanesulfonyl)benzene(900174-43-8)
• EPA Substance Registry System: 1-BroMo-2-(isopropanesulfonyl)benzene(900174-43-8)

Safety Data

• Hazardous Substances Data: 900174-43-8(Hazardous Substances Data)

Usage

Description

A chemical compound with a bromine atom and a sulfonyl group attached to a benzene ring.

Reactivity

Highly reactive and potent electrophile, commonly used as a sulfonating agent in organic synthesis.

Applications

Valuable intermediate in the production of pharmaceuticals, agrochemicals, and dyes, and studied for potential use in medicinal chemistry as a building block in the synthesis of bioactive molecules.

Precautions

Toxic, flammable, and potentially hazardous to the environment, should be handled and used with caution in a controlled laboratory setting.

Upstream product

• 6320-02-1 o-bromothiophenol 
• 75-26-3 isopropyl bromide 
• 245739-32-6 2-isopropylsulfanyl-1-bromobenzene 

Downstream Products

• 1032900-25-6 5-chloro-N²-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-N⁴-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine 
• 900174-44-9 tert-butyl 2-(2-(isopropylsulfonyl)phenyl)-1H-pyrrole-1-carboxylate 

Relevant articles and documents

Ceritinib intermediate and method for preparing ceritinib

The invention relates to a ceritinib intermediate and a method for preparing ceritinib. A ceritinib intermediate compound is 4-isopropoxy-5-guanidyl-2-N-substituted piperidine-4-base toluene nitrate (VII). The method includes carrying out substation reaction on 2-nitro-4,5-dimethyl chlorobenzene and isopropyl alcohol in the presence of alkali to generate compounds III; carrying out condensation onthe compounds III and halogenated acetaldehyde di-acetal and carrying out reduction ring formation by ammonia-ammonium chloride-sodium borohydride to obtain compounds IV; carrying out amino protection to obtain compounds V; carrying out catalytic hydrogenation in solvents and carrying out nitro reduction to obtain amino so as to obtain compounds VI; carrying out reaction on the compounds VI and cyanamide to obtain compounds VII. The ceritinib can be prepared from the compounds VII by the aid of the method. The ceritinib intermediate and the method have the advantages of inexpensive and easilyavailable raw materials, simplicity and convenience in operation, high elementary reaction selectivity, low wastewater quantity and green environmental protection.

PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS

The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.